Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

UCB Stock News

UCBJFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

UCB (UCBJF) Forecast

News

Earnings UCB (UCBJF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest UCB Stock News | OTC:UCBJF | Benzinga

Get the latest news on UCB stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on UCB performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, November 20, 2024

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Vandana Singh
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Vandana Singh

Tuesday, September 24, 2024

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Vandana Singh

Tuesday, September 10, 2024

Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Vandana Singh

Thursday, August 29, 2024

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Vandana Singh

Monday, August 26, 2024

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
Vandana Singh

Tuesday, January 02, 2024

There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Vandana Singh

Thursday, September 28, 2023

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Vandana Singh

Thursday, August 31, 2023

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Vandana Singh

Tuesday, June 27, 2023

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
Vandana Singh

Tuesday, February 14, 2023

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Vandana Singh

Monday, March 28, 2022

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
Vandana Singh

Tuesday, February 08, 2022

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Vandana Singh

Friday, January 21, 2022

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
Vandana Singh

Wednesday, January 19, 2022

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Vandana Singh

Wednesday, August 25, 2021

UCB Gets EU Approval For Bimekizumab In Psoriasis
Vandana Singh

Thursday, October 10, 2019

Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB
Shanthi Rexaline

Friday, July 13, 2018

Amgen, UCB Resubmit BLA for EVENITY to FDA
Benzinga

Sunday, July 16, 2017

Amgen, UCB Announce FDA Provides CRL for BLA for EVENITY
Benzinga

Sunday, April 02, 2017

Amgen, UCB Report New Data Examining The Option Of A Second Course Of Treatment With EVENITY at ENDO 2017
Benzinga

Thursday, January 19, 2017

Dermira Announces Final CIMZIA Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Benzinga

Friday, February 19, 2016

FDA Approves Briviact to Treat Partial Onset ...
Benzinga

Friday, May 15, 2015

The FDA's Authority Challenged By Mallinckrodt
Benzinga

Thursday, January 30, 2014

Biogen, UCB Annouince Agreements to Commercialize MS, Hemophilia Therapies in Asia
Benzinga

Wednesday, January 01, 2014

Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show Significant Increases In Bone Mineral Density
Benzinga

Tuesday, January 25, 2011

Boost for VRX-GSK Epilepsy Drug - Analyst Blog
Benzinga
Earnings Preview: Abbott Labs - Analyst Blog
Benzinga

Wednesday, January 12, 2011

UCB's Progress On-Track - Analyst Blog
Benzinga

Wednesday, December 15, 2010

UCB Commences Patient Enrolment - Analyst Blog
Benzinga

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved